Federal Government Scrutinizing Sales Rep Dealings With Trial Results
This article was originally published in The Gray Sheet
Executive Summary
Medical device manufacturers who let their sales representatives disseminate clinical trial results for unapproved devices or off-label indications are skating on thin ice, according to the Department of Justice and the HHS Office of Inspector General
You may also be interested in...
Medtronic To Track Sales Contacts, Pay $40 Mil. To Settle Kickback Probe
Medtronic will begin recording all transactions between its spine product sales personnel and physicians as part of a settlement agreement with the U.S. Department of Justice
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.